• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sarepta Therapeutics Set to Join S&P MidCap 400

    5/29/24 5:48:00 PM ET
    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $JNJ alert in real time by email

    NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    June 3, 2024

    S&P MidCap 400

    Addition

    Sarepta Therapeutics

    SRPT

    Health Care

    June 3, 2024

    S&P MidCap 400

    Deletion

    Shockwave Medical

    SWAV

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    index_services@spglobal.com

    Media Inquiries

    spdji.comms@spglobal.com

    Cision View original content:https://www.prnewswire.com/news-releases/sarepta-therapeutics-set-to-join-sp-midcap-400-302158643.html

    SOURCE S&P Dow Jones Indices

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $SPGI
    $SRPT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    5/13/2026$265.00Market Perform → Outperform
    Leerink Partners
    Johnson & Johnson
    $JNJ
    4/8/2026$250.00Buy
    TD Cowen
    S&P Global Inc.
    $SPGI
    2/17/2026$575.00Buy
    BofA Securities
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

    Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preserving immune function New exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody levels and even greater clinical response rates of participants in the nipocalimab treatment group Previously reported data from the Phase 2 study showed nipocalimab reduced Sjögren's disease activity and severity, with potential to address systemic manifestations and the most burdensome patient-reported symptoms including dryness, fatigue and painNipocalimab is the only FcRn blocker

    6/3/26 12:03:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    American Business Bank Ranked 6th in Top 50 Community Banks With Assets Between $3 Billion and $10 Billion for 2025

    AMERICAN BUSINESS BANK (ABB) ((AMBZ) was ranked number six in S&P Global Market Intelligence's Top 50 Community Banks with assets between $3 billion and $10 billion for 2025, based on financials for the year ended December 31, 2025. "We are incredibly honored by the bank's exceptional achievements in 2025. This recognition underscores the long-term benefits of our disciplined conservative approach to managing the bank, while partnering and serving the best middle-market businesses in Southern California," said Leon Blankstein, Director, Chief Executive Officer and President of ABB. The ranking evaluates top deposit franchises among US banks with between $3 billion and $10 billion in tot

    6/2/26 9:05:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Sarepta Therapeutics to Participate in Upcoming Investor Conferences

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club in Miami Beach, Fla. The presentation for the Goldman Sachs conference will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and will be arc

    6/1/26 4:30:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    SEC Filings

    View All

    SEC Form SD filed by Johnson & Johnson

    SD - JOHNSON & JOHNSON (0000200406) (Filer)

    5/27/26 4:15:25 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    5/26/26 8:45:08 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - S&P Global Inc. (0000064040) (Filer)

    5/21/26 4:25:43 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Johnson & Johnson from Market Perform to Outperform and set a new price target of $265.00

    5/13/26 7:59:34 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen resumed coverage on Johnson & Johnson with a new price target

    TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00

    4/8/26 8:36:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $575.00

    2/17/26 7:30:15 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moritz Robert Edward Jr. bought $500,001 worth of shares (1,152 units at $434.03) (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    5/4/26 4:19:22 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    CEO, S&P Dow Jones Indices Clay Catherine R bought $1,078,475 worth of shares (2,500 units at $431.39) (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    5/4/26 4:18:28 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    CEO & President Cheung Martina bought $998,297 worth of shares (2,322 units at $429.93), increasing direct ownership by 9% to 27,518 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    5/1/26 4:07:01 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP, CTTO Bhathena Firdaus

    4 - S&P Global Inc. (0000064040) (Issuer)

    5/5/26 4:10:28 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 134% to 24,911 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    5/4/26 4:58:59 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Moritz Robert Edward Jr. bought $500,001 worth of shares (1,152 units at $434.03) (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    5/4/26 4:19:22 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    FedEx Freight Holding Set to Join Dow Jones Transportation Average

    NEW YORK, May 27, 2026 /PRNewswire/ -- FedEx Freight Holding Company Inc. (NYSE:FDXF) will replace American Airlines Group Inc. (NASD:AAL) in the Dow Jones Transportation Average (DJTA) effective prior to the open of trading on Monday, June, 1, 2026. Dow Jones Transportation Average constituent FedEx Corp. (NYSE:FDX) is spinning off FedEx Freight Holding Company in a transaction expected to be completed on June 1. Post spin-off, parent FedEx will remain in the DJTA. American Airlines Group has a low weight in the index of less than one-half of one percentage point caused by its low share price. The Dow Jones Transportation Average is a price weighted index, and thus very low-priced stocks ha

    5/27/26 11:13:00 PM ET
    $AAL
    $FDX
    $SPGI
    Air Freight/Delivery Services
    Consumer Discretionary
    Finance: Consumer Services
    Finance

    FedEx Freight Holding Company Set to Join S&P 500; EPAM Systems and Dave to Join S&P SmallCap 600

    NEW YORK, May 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:  FedEx Freight Holding Company (NYSE:FDXF) will replace EPAM Systems Inc. (NYSE:EPAM) in the S&P 500, and EPAM Systems will replace Shutterstock Inc. (NYSE:SSTK) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, June 2. S&P 500 & 100 constituent FedEx Corp. (NYSE:FDX) is spinning off FedExFreight Holding in a transaction expected to be completed June 1. Post spin-off, the parent FedEx will remain in the S&P 500 and 100. EPAM Systems is more representative of the small-cap market space. Shutterstock is anticipated to be acquired in a deal t

    5/27/26 6:30:00 PM ET
    $AMWD
    $DAVE
    $EPAM
    Forest Products
    Basic Materials
    Finance: Consumer Services
    Finance

    Universal Technical Institute and Peloton Interactive Set to Join S&P SmallCap 600

    NEW YORK, May 21, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, May 27. Universal Technical Institute Inc. (NYSE:UTI) will replace Veris Residential Inc. (NYSE:VRE). Affinius Capital and Vista Hill Partners are acquiring Veris Residential in a deal expected to be completed soon, pending final closing conditions.Peloton Interactive Inc. (NASD: PTON) will replace Enviri Corp. (NYSE:NVRI). Enviri is spinning off certain operations and assets later this month into a new publicly traded company. Post spin-off, Veolia Environment SA will acquire the remaining parent entity. The new publicly

    5/21/26 6:03:00 PM ET
    $NVRI
    $PTON
    $SPGI
    Diversified Commercial Services
    Miscellaneous
    Recreational Games/Products/Toys
    Consumer Discretionary

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the w

    5/27/26 4:22:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Announces Leadership Change for Market Intelligence, Evolution of Enterprise Data, Technology & Transformation

    Saugata Saha to depart the Company July 30, 2026Enterprise Data, Technology & Transformation Organizations Combine to Unlock Greater Value and InnovationNEW YORK, May 26, 2026 /PRNewswire/ -- S&P Global (NYSE: SPGI) announced today that Saugata Saha, President of S&P Global Market Intelligence and Chief Enterprise Data Officer, has decided to leave the company to pursue another opportunity. Mr. Saha will remain with S&P Global through July 30, 2026, to support transition. "Saugata is a respected leader and a valued member of our Executive Leadership Team. He leaves Market Intell

    5/26/26 8:47:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Announces Approval of Separation of Mobility Global

    NEW YORK, May 21, 2026 /PRNewswire/ -- S&P Global Inc. (NYSE:SPGI) ("S&P Global") today announced that its Board of Directors (the "Board") has approved the previously announced separation of its Mobility division, and the creation of an independent, public company, Mobility Global Inc. ("Mobility Global"). The separation will be achieved through a pro rata distribution of 100% of the outstanding shares of Mobility Global common stock to the holders of S&P Global common stock. S&P Global shareholders will receive one share of Mobility Global common stock for every share of S&P G

    5/21/26 7:12:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

    SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

    2/13/24 5:13:59 PM ET
    $SWAV
    Medical/Dental Instruments
    Health Care